Dragos Fortofoiu

Dr. Dragos Fortofoiu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RSRobert Emmanuel Serban
Robert Emmanuel Serban
DPDragoş-Marian Popescu
Dragoş-Marian Popescu
Mihail Virgil BoldeanuMihail Virgil Boldeanu
Mihail Virgil Boldeanu
DFDan Nicolae Florescu
Dan Nicolae Florescu
MȘMircea-Sebastian Șerbănescu
Mircea-Sebastian Șerbănescu
CVCristin Constantin Vere
Cristin Constantin Vere
Background: Colorectal cancer affects a large number of patients worldwide, with numerous factors being involved in its etiopathogenesis and chronic inflammation playing an essential role in tumor development. In this study, we analyzed and compared several markers of inflammation that are relatively easy to obtain for a rapid and accurate diagnosis and prognosis. Methods: This study included 219 patients diagnosed with colorectal cancer, analyzing the inflammation scores derived from their blood cells and inflammatory circulating proteins. These inflammatory markers are neutrophil-to-lymphocyte ratio—NLR; platelet-to-lymphocyte ratio—PLR; lymphocyte-to-monocyte ratio—LMR; systemic immune inflammation index—SII; systemic inflammatory response index—SIRI; aggregate index of systemic inflammation—AISI; derived neutrophil-to-lymphocyte ratio—dNLR; C-reactive protein-to-albumin ratio—CAR; and fibrinogen-to-albumin ratio—FAR. In the analysis of patients with colorectal cancer, we have also introduced two new recently developed inflammatory markers: the cumulative inflammatory index (IIC) and the ratio between the mean corpuscular volume and lymphocytes (MCVL). This study aimed to correlate the inflammatory markers’ levels with the colorectal cancer diagnostic stage, the tumor and clinical characteristics of the colorectal cancer patients, and 36 months’ survival time and to evaluate the diagnostic and prognostic capacity and accuracy of these inflammatory markers in this type of cancer. Results: We showed that the levels of the analyzed inflammation markers correlate with the TNM stage, the tumor pathological differentiation grade, the age and gender of the patients, and overall survival, with their increased levels being associated with a lower survival rate. Conclusions: The analyzed markers, which are easy to perform right from the patient’s admission, can be helpful both in diagnosis and, mostly, in prognosis, sustaining the role of inflammation in cancer. By comparing them, we showed which one can be useful for increased sensitivity and specificity in the diagnosis and prognosis of colorectal cancer patients.

11 November 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
Vlad PadureanuVlad Padureanu
Vlad Padureanu
Virginia Maria RadulescuVirginia Maria Radulescu
Virginia Maria Radulescu
CMCristiana Moise
Cristiana Moise
MMMarius Cristian Marinaș
Marius Cristian Marinaș
Padureanu RodicaPadureanu Rodica
Padureanu Rodica
BLBOLDEANU LIDIA
BOLDEANU LIDIA
Background/Objectives: Oxidative stress contributes to the pathogenesis of cirrhosis, but its value as a clinical biomarker remains uncertain. Methods: We retrospectively analysed 90 patients with decompensated cirrhosis. Serum malondialdehyde (MDA) and 8-epi-prostaglandin F2α (8-iso-PGF2α) were measured at admission. Biomarker levels were compared between Child–Pugh classes B and C, across hepatic encephalopathy grades, and ascites severity, using Mann–Whitney, Kruskal–Wallis, and Spearman correlation tests. Results: Median MDA did not differ significantly between Child–Pugh classes B and C (2.67 [2.10–3.20] vs. 2.45 [1.98–3.05] μmol/L; p = 0.331), nor across ascites categories (p = 0.453). Similarly, 8-iso-PGF2α values did not vary between Child–Pugh classes (255.8 [220.0–310.0] vs. 250.1 [210.0–295.0] pg/mL; p = 0.784) or ascites groups (p = 0.828). Spearman analysis showed no significant correlations with albumin, INR, bilirubin, creatinine, or age, except for a non-significant trend with bilirubin (ρ = −0.18, p = 0.09). Importantly, MDA levels increased significantly across encephalopathy grades (p = 0.021), suggesting a link between systemic oxidative stress and neuropsychiatric impairment. Conclusions: In this clinical cohort, oxidative stress biomarkers did not provide discriminatory value for staging by Child–Pugh or ascites, but MDA was associated with encephalopathy severity. These findings highlight both the limitations and potential clinical relevance of oxidative stress markers in cirrhosis management.

Verified
Journal Article
Open access
PDF file
Vlad PadureanuVlad Padureanu
Vlad Padureanu
Daniel Cosmin CarageaDaniel Cosmin Caragea
Daniel Cosmin Caragea
DPDenisa Pirscoveanu
Denisa Pirscoveanu
DDDop Dalia
Dop Dalia
AMAlexandru Claudiu Munteanu
Alexandru Claudiu Munteanu
Padureanu RodicaPadureanu Rodica
Padureanu Rodica
There is a substantial correlation between cardiac dysfunction and elevated mortality in sepsis. Impaired myocardial perfusion, direct myocardial injury, and mitochondrial dysfunction are all part of the complex pathophysiology of sepsis-induced myocardial dysfunction. Recent evidence has shown the critical role mitochondrial dysfunction plays in the development of sepsis-induced myocardial dysfunction. In order to prevent and treat sepsis-induced myocardial dysfunction, a variety of drugs have been proposed. However, patient outcomes have not been appreciably enhanced by this therapy. This underscores the need for novel treatment approaches that target the specific pathways underlying cardiac dysfunction in sepsis. The prognosis is greatly impacted by sepsis-induced cardiac dysfunction, monitoring it is crucial. Clinicians employ a mix of clinical evaluations, hemodynamic monitoring, echocardiography, and bSICiomarkers to efficiently monitor this illness. The combined application of these techniques provides a comprehensive evaluation of cardiac function, thereby supporting timely optimization of treatment strategies. Treatments for septic shock and established sepsis will be beneficial for patients with this condition. However, there is little information and evidence about more targeted therapy, except than general management with vasopressors, inotropes, and fluid resuscitation. This study provides an outline of current knowledge on the pathophysiological mechanisms underlying sepsis-induced cardiac dysfunction, as well as the effects of monitoring and current treatments on sepsis-induced myocardial dysfunction.

5 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
IDIoana Gabriela Dragne
Ioana Gabriela Dragne
Bogdan Silviu UngureanuBogdan Silviu Ungureanu
Bogdan Silviu Ungureanu
DFDragos Fortofoiu
Dragos Fortofoiu
Vlad PadureanuVlad Padureanu
Vlad Padureanu
BLBOLDEANU LIDIA
BOLDEANU LIDIA
Mihail Virgil BoldeanuMihail Virgil Boldeanu
Mihail Virgil Boldeanu
Background: Oxidative stress plays a significant role in inflammatory bowel disease (IBD), yet the clinical relevance of specific lipid peroxidation markers remains insufficiently defined. This study evaluated serum levels of 8-epi-prostaglandin F2α (8-epi-PGF2α), an isoprostane generated through non-enzymatic lipid oxidation, and examined its relationship with antioxidant enzymes and clinical disease activity in ulcerative colitis (UC) and Crohn’s disease (CD). Methods: Eighty-seven patients (55 UC and 32 CD) were assessed for serum 8-epi-PGF2α, superoxide dismutase 1 (SOD1), and glutathione peroxidase 1 (GPX1), and classified as having mild, moderate, or severe disease. Statistical analyses included comparative analysis, two-way ANOVA, multiple linear regression, and Ridge logistic regression. To address potential dietary confounding, total energy intake, Mediterranean Diet Score (MDS), and antioxidant supplement use were incorporated into the regression models. Results: Serum levels of 8-epi-PGF2α and GPX1 were significantly higher in UC than in CD (ρ = 0.001 and p = 0.042), and both increased with greater disease severity (p < 0.001 and p = 0.001). In UC, 8-epi-PGF2α positively correlated with high-sensitivity C-reactive protein (hs-CRP), white blood cells (WBC), and Truelove–Witts Index (TWI), and negatively with hemoglobin (False Discovery Rate (FDR)-adjusted q < 0.100). In CD, it correlated with the Harvey–Bradshaw Index (HBI) and disease duration (FDR-adjusted q < 0.050). Inter-biomarker analyses showed a strong association between 8-epi-PGF2α and GPX1 in UC (ρ = 0.677, p < 0.0001, FDR < 0.0001), suggesting coordinated activation of oxidative and antioxidant pathways. The observed associations remained consistent after adjustment for dietary factors, supporting the robustness of the findings. Because these results are cross-sectional, they cannot establish causality and should be interpreted with caution. Conclusions: Nevertheless, 8-epi-PGF2α emerges as a promising non-invasive biomarker for assessing oxidative stress and disease activity in IBD, with potential clinical applicability for patient monitoring and therapeutic evaluation.

28 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMariana-Emilia Caragea
Mariana-Emilia Caragea
Daniel Cosmin CarageaDaniel Cosmin Caragea
Daniel Cosmin Caragea
MNMarius Novac
Marius Novac
BLBOLDEANU LIDIA
BOLDEANU LIDIA
Mohamed-Zakaria AssaniMohamed-Zakaria Assani
Mohamed-Zakaria Assani
CVCristin Constantin Vere
Cristin Constantin Vere
Background: Staphylococcus aureus — particularly methicillin-resistant S. aureus (MRSA) — remains one of the leading causes of skin and soft tissue infections (SSTIs) worldwide. Patients with renal edema, including those with nephrotic syndrome and chronic kidney disease (CKD), represent a population of increased susceptibility due to combined barrier dysfunction, immune impairment, and altered pharmacokinetics. Despite its substantial clinical relevance, the mechanistic relationship between renal edema and cutaneous staphylococcal infection has received limited integrative attention. Objectives: This narrative review aims to: (1) examine the pathophysiological mechanisms through which renal edema predisposes to cutaneous S. aureus infection; (2) characterize the virulence mechanisms that facilitate bacterial persistence and invasion in the renal host; (3) describe the clinical spectrum of SSTIs in this population; (4) evaluate current and emerging therapeutic strategies adapted to renal dysfunction; and (5) discuss the management challenges of severe S. aureus infection in critically ill renal patients. Methods: Search terms included combinations of Staphylococcus aureus, MRSA, skin and soft tissue infections, renal edema, nephrotic syndrome, chronic kidney disease, ICU, vancomycin pharmacokinetics, augmented renal clearance, and anti-virulence therapy. Priority was given to clinical guidelines, systematic reviews, translational studies, and landmark investigations relevant to the pathophysiology and management of cutaneous staphylococcal infection in renal disease. Results: Three converging pathophysiological axes appear to underlie the increased susceptibility of patients with renal edema to cutaneous S. aureus infection: (1) mechanical barrier disruption caused by edema-associated skin tension, blistering, fissuring, and proteinaceous exudate; (2) nephrotic and uremic immunodeficiency, including urinary immunoglobulin loss, neutrophil dysfunction mediated by protein-bound uremic retention solutes (PBURS), complement depletion, and T-cell dysregulation; and (3) lymphatic dysfunction impairing regional immune surveillance and antigen clearance. S. aureus exploits these abnormalities through adhesins, toxin-mediated tissue injury, biofilm formation, and coordinated immune evasion pathways regulated in part by the ArlRS/MgrA cascade. In critically ill patients, management is further complicated by major pharmacokinetic variability, including augmented renal clearance, expanded volume of distribution, and extracorporeal renal support, necessitating individualized dosing strategies and AUC/MIC-guided vancomycin monitoring. Emerging anti-virulence approaches targeting alpha-toxin, quorum-sensing systems, and immune evasion pathways represent promising adjunctive therapeutic strategies. Conclusions: Renal edema creates a biologically permissive environment for cutaneous S. aureus infection through the interaction of barrier dysfunction, immune impairment, and altered antimicrobial pharmacokinetics. Optimal management requires early recognition, renal-adapted antimicrobial therapy, therapeutic drug monitoring, source control, and multidisciplinary care. Continued development of anti-virulence and immunomodulatory therapies may further improve outcomes in this vulnerable patient population.

16 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
IMIulia Cristina Marginean
Iulia Cristina Marginean
CMCristina Maria Marginean
Cristina Maria Marginean
SCSergiu Marian Cazacu
Sergiu Marian Cazacu
GIGeorge Alexandru Iacob
George Alexandru Iacob
DFDragos Fortofoiu
Dragos Fortofoiu
CVCristin Constantin Vere
Cristin Constantin Vere
Background: Increased intestinal permeability is a proposed pathophysiological mechanism in irritable bowel syndrome (IBS), and zonulin, a putative regulator of tight junctions, has been investigated as a non-invasive serum biomarker. However, the diagnostic utility of circulating zonulin in IBS remains controversial. Objectives: To systematically review studies comparing serum or plasma zonulin concentrations between adult IBS patients and healthy controls, and to evaluate the influence of assay methodology on reported outcomes. Methods: A systematic literature search of PubMed was performed up to April 2026; the most recent eligible study was published in June 2024. Studies that enrolled adults with IBS diagnosed by Rome criteria, included healthy control groups, and measured zonulin by enzyme-linked immunosorbent assay (ELISA) were eligible. Studies lacking a healthy control group, non-original reports, animal studies, and mixed functional gastrointestinal disorder cohorts without extractable IBS data were excluded. Findings were synthesised narratively due to substantial methodological heterogeneity and concerns regarding the validity of commercially available zonulin kits. Risk of bias was assessed using the Newcastle–Ottawa Scale for case–control studies; six studies were at low risk and two at intermediate risk. The review is reported in accordance with the PRISMA 2020 statement, and this abstract follows the PRISMA 2020 for Abstracts checklist. Results: Eight case–control studies were included, comprising 421 IBS patients and 428 controls. Of the seven studies contributing to the primary synthesis, two reported significantly elevated zonulin in IBS, one produced opposite results with two different assays applied to the same samples, and four found no significant difference compared with controls. An eighth study, which combined IBS with inflammatory bowel disease and did not report IBS-specific data, was retained as supportive, non-primary evidence. Crucially, the studies employed different ELISA kits (ALPCO, Cusabio, Immundiagnostik, Zellbio) and different units of measurement. Independent validation studies have demonstrated that the most frequently used commercial kits do not recognise the pre-haptoglobin-2 molecule claimed to be zonulin, but instead detect haptoglobin, complement C3, or properdin. The only study employing a monoclonal antibody specific for pre-haptoglobin-2 observed lower, rather than higher, concentrations in IBS. Conclusions: The existing literature based on commercial ELISAs cannot determine whether pre-HP2/zonulin is altered in IBS, and the single genotype-controlled monoclonal assay suggests lower, not higher, concentrations in IBS. The disparate results are largely attributable to the application of ELISA kits that lack analytical specificity for the proposed target. Future research must use analytically validated assays, such as monoclonal antibody-based methods with concomitant genotyping for haptoglobin polymorphisms, before zonulin can be considered a meaningful biomarker in IBS. Funding: The Article Processing Charges were funded by the University of Medicine and Pharmacy of Craiova, Romania. Registration: The review was not prospectively registered; a retrospective protocol registration is available on OSF [10.17605/OSF.IO/MFA6J].